1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatitis - Drugs In Development, 2022, provides an overview of the Pancreatitis (Gastrointestinal) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Pancreatitis is an inflammation of pancreas. Symptoms include upper abdominal pain, nausea, vomiting, and tenderness when touching the abdomen, weight loss and upper abdominal pain. Predisposing factors include alcoholism, smoking, family history of pancreatitis, infection, injury to the abdomen and pancreatic cancer. Treatment includes antibiotics and medication to relieve pain.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Pancreatitis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Pancreatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pancreatitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Pancreatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 8, 2, 16, 2 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.
Pancreatitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Pancreatitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pancreatitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pancreatitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatitis (Gastrointestinal)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pancreatitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pancreatitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- REPORT COVERAGE
- Pancreatitis - Overview
- Pancreatitis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Pancreatitis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Pancreatitis - Companies Involved in Therapeutics Development
- Pancreatitis - Drug Profiles
- Pancreatitis - Dormant Projects
- Pancreatitis - Discontinued Products
- Pancreatitis - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Pancreatitis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pancreatitis - Pipeline by AcelRx Pharmaceuticals Inc, 2022
- Pancreatitis - Pipeline by Angion Biomedica Corp, 2022
- Pancreatitis - Pipeline by Ariel Precision Medicine Inc, 2022
- Pancreatitis - Pipeline by Beijing GeneCradle Technology Co Ltd, 2022
- Pancreatitis - Pipeline by Bessor Pharma LLC, 2022
- Pancreatitis - Pipeline by CalciMedica Inc, 2022
- Pancreatitis - Pipeline by Centeer BioTherapeutics Ltd Co, 2022
- Pancreatitis - Pipeline by Cypralis Ltd, 2022
- Pancreatitis - Pipeline by D&D Pharmatech Co Ltd, 2022
- Pancreatitis - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
- Pancreatitis - Pipeline by DiaMedica Therapeutics Inc, 2022
- Pancreatitis - Pipeline by Evive Biotech, 2022
- Pancreatitis - Pipeline by GNT Pharma Co Ltd, 2022
- Pancreatitis - Pipeline by GSK plc, 2022
- Pancreatitis - Pipeline by Healx Ltd, 2022
- Pancreatitis - Pipeline by HighTide Therapeutics Inc, 2022
- Pancreatitis - Pipeline by JD Bioscience Inc, 2022
- Pancreatitis - Pipeline by Johnson & Johnson, 2022
- Pancreatitis - Pipeline by Kynos Therapeutics Ltd, 2022
- Pancreatitis - Pipeline by Lamassu Pharma LLC, 2022
- Pancreatitis - Pipeline by LipimetiX Development Inc, 2022
- Pancreatitis - Pipeline by Mallinckrodt Plc, 2022
- Pancreatitis - Pipeline by Panbela Therapeutics Inc, 2022
- Pancreatitis - Pipeline by Path BioAnalytics Inc, 2022
- Pancreatitis - Pipeline by PNB Vesper Life Science Pvt Ltd, 2022
- Pancreatitis - Pipeline by Regeneron Pharmaceuticals Inc, 2022
- Pancreatitis - Pipeline by Samsung Bioepis Co Ltd, 2022
- Pancreatitis - Pipeline by SCM lifescience Co Ltd, 2022
- Pancreatitis - Pipeline by Shionogi & Co Ltd, 2022
- Pancreatitis - Dormant Projects, 2022
- Pancreatitis - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Pancreatitis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AcelRx Pharmaceuticals Inc
- Angion Biomedica Corp
- Ariel Precision Medicine Inc
- Beijing GeneCradle Technology Co Ltd
- Bessor Pharma LLC
- CalciMedica Inc
- Centeer BioTherapeutics Ltd Co
- Cypralis Ltd
- D&D Pharmatech Co Ltd
- Daewoong Pharmaceutical Co Ltd
- DiaMedica Therapeutics Inc
- Evive Biotech
- GNT Pharma Co Ltd
- GSK plc
- Healx Ltd
- HighTide Therapeutics Inc
- JD Bioscience Inc
- Johnson & Johnson
- Kynos Therapeutics Ltd
- Lamassu Pharma LLC
- LipimetiX Development Inc
- Mallinckrodt Plc
- Panbela Therapeutics Inc
- Path BioAnalytics Inc
- PNB Vesper Life Science Pvt Ltd
- Regeneron Pharmaceuticals Inc
- Samsung Bioepis Co Ltd
- SCM lifescience Co Ltd
- Shionogi & Co Ltd
